Improving nutritional status and frailty in patients with motor neuron disease using silkworm pupa powder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of silkworm pupa powder on the nutritional status and frailty of patients diagnosed with motor neuron disease, particularly amyotrophic lateral sclerosis (ALS). The intervention involves administering either standard or ultra-low doses of silkworm pupa powder to participants who meet specific eligibility criteria. The study aims to assess improvements in muscle strength, weight, and overall health status among these patients. Participants will also provide biological samples for further analysis during the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Informed Consent Form (ICF); willing to follow and capable of completing all trial procedures.
* Gender is not limited, age at the time of signing ICF: ≥18 years old, ≤80 years old; if the ALS patient is at least 18 years old, then the weight must be over 40 kilograms.
* Diagnosis conforms to the confirmed and probable ALS in the ALS2020 diagnostic criteria (Gold Coast Criteria).
* Clinical, neurophysiological, or pathological examination confirms evidence of lower motor neuron involvement.
* Frailty Phenotype scale (FP) ≥1.
* Exclude other diseases.
* Agree to provide peripheral blood, fecal, and urine samples for biomarker analysis during the study period.

Exclusion Criteria:

* Patients with other neurological diseases similar to ALS symptoms or affecting drug efficacy evaluation, such as cervical spondylosis, lumbar disease, dementia, etc.
* Patients with other autoimmune diseases, such as Multiple Sclerosis (MS), Polymyositis, Myasthenia Gravis, Guillain-Barré Syndrome, Ankylosing Spondylitis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vitiligo, etc.
* Severe renal insufficiency: Creatinine clearance \< 30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency diseases.
* Severe liver damage: ALT, AST \> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.
* Patients with severe pulmonary function insufficiency such as Chronic Obstructive Pulmonary Disease (COPD), pulmonary fibrosis, etc.
* During the screening period, patients with acute myocardial infarction or interventional treatment within the last 6 months, heart failure patients (classified as NYHA class III-IV patients).
* Patients with other severe primary diseases of the nervous system, heart, lungs, hematopoietic system, or endocrine system, and mental illness patients.
* Those suspected or confirmed to have a history of alcohol or drug abuse.
* Expected survival ≤ 3 months.
* Pregnant or breastfeeding women, subjects of reproductive age (including male subjects who have had heterosexual intercourse and their female partners with childbearing potential) who plan to become pregnant or are unwilling to take effective contraceptive measures from the start of screening to 3 months after discontinuing medication.
* Those who are allergic to known ingredients of the trial products; or have a history of drug allergies or severe allergic diseases (anaphylactic shock, etc.).
* During the study, individuals assessed by researchers as potential drug abusers who may affect the efficacy of therapeutic drugs.
* Presence of other severe physical or mental diseases or abnormal laboratory tests that may increase the risk of participating in the study and patients deemed unsuitable for participation by the researcher.
* Patients with malignant tumors.

Where it's running

• Hangzhou First People's Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Ma Buqing Attending Physician
• Email: 757318708@qq.com
• Phone: 0571-56007429

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Healing ALS Registry (HAROS) for people with ALS, MND, and PLS

  This fully remote registry asks people with ALS, MND, or PLS to enter monthly health, treatment, and lifestyle information to try to see which therapies and education relate to better physical outcomes.

  Recruiting Healing Advocates Registry and Ministry · Park City, Utah · NCT07233148

• Early detection of respiratory impairment in ALS using breathing, MRI, and blood markers

  This study tests whether breathing patterns, MRI changes in the brainstem and spinal cord, and blood markers can reveal early ALS signs, especially in people with genetic risk or early symptoms.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07844590

• Plasmapheresis for ALS with anti-NRIP autoantibody

  This study tests whether a few plasmapheresis sessions can help people with ALS who have anti-NRIP autoantibody by keeping the antibody levels low.

  Recruiting National Taiwan University Hospital · Taipei City, Taipei · NCT07726563

• Implanted brain interface to let people with severe paralysis control assistive devices

  It will try an implanted brain interface that records and stimulates brain signals so adults with severe paralysis can control assistive devices and receive sensory feedback.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07521930

• Do video recordings of multidisciplinary clinics help ALS patients and caregivers?

  This study tests whether providing a video recording of ALS multidisciplinary clinic visits, in addition to written notes, helps patients and their caregivers manage information and feel better about care.

  Recruiting Trustees of Dartmouth College · Scottsdale, Arizona and 6 other locations · NCT07454733

• Measuring Hsp90 levels in the human brain

  This trial tests whether a PET tracer called [11C]HSP990 can measure Hsp90 levels in the brains of healthy adults and people with Parkinson's disease, Alzheimer's disease, or ALS.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaam-Brabant · NCT07380204

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.